InflaRx NV
NASDAQ:IFRX

Watchlist Manager
InflaRx NV Logo
InflaRx NV
NASDAQ:IFRX
Watchlist
Price: 2.08 USD 0.97% Market Closed
Market Cap: 122.5m USD
Have any thoughts about
InflaRx NV?
Write Note

Wall Street
Price Targets

IFRX Price Targets Summary
InflaRx NV

Wall Street analysts forecast IFRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IFRX is 8.42 USD with a low forecast of 5.05 USD and a high forecast of 13.65 USD.

Lowest
Price Target
5.05 USD
143% Upside
Average
Price Target
8.42 USD
305% Upside
Highest
Price Target
13.65 USD
556% Upside
InflaRx NV Competitors:
Price Targets
BAVA
Bavarian Nordic A/S
60% Upside
ANIK
Anika Therapeutics Inc
59% Upside
LEGN
Legend Biotech Corp
106% Upside
GBIO
Generation Bio Co
421% Upside
REGN
Regeneron Pharmaceuticals Inc
50% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
27% Upside
VCYT
Veracyte Inc
11% Upside
1952
Everest Medicines Ltd
21% Downside

Revenue
Forecast

Revenue Estimate
InflaRx NV

The compound annual growth rate of InflaRx NV's revenue for the next 3 years is 620%.

N/A
Past Growth
620%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
InflaRx NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
InflaRx NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IFRX's stock price target?
Price Target
8.42 USD

According to Wall Street analysts, the average 1-year price target for IFRX is 8.42 USD with a low forecast of 5.05 USD and a high forecast of 13.65 USD.

What is InflaRx NV's Revenue forecast?
Projected CAGR
620%

The compound annual growth rate of InflaRx NV's revenue for the next 3 years is 620%.

Back to Top